Special Issue "Photodynamic Therapy in Cancer"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 9200
Interests: photodynamic therapy, tumor imaging-guided surgery; targeted drug delivery and nanomedicines; light and nanomaterial-based combination therapies
Photodynamic therapy (PDT) is clinically approved for the treatment of various cancer and non-cancer applications. It exerts direct efficacy in destroying primary tumors, utilizing a light-activable molecule—termed a photosensitizer—light of an appropriate wavelength, along with oxygen, to impart cytotoxicity via the generation of reactive molecular species. In addition to therapeutic effects, photosensitizer-mediated fluorescence can also be used for image-guided surgery. Benefiting from the rapid development of nanotechnology, sophisticated targeting approaches and the emergence of nanocarriers for the codelivery of multiple therapeutics, PDT in combination with chemotherapy, photothermal therapy, radiotherapy, and immunotherapy can significantly enhance treatment outcomes, minimizing the off-target effects.
This Special Issue, Photodynamic Therapy of Cancer, aims to publish the latest research and translational work in the field of PDT in original articles related to nanodelivery carriers, photochemical and photobiological aspects, targeted drug delivery, tumor image-guided surgery, immunogenic cell death, and PDT-based multimodal therapies of cancer.
Dr. Shazia Bano
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- photodynamic therapy
- targeted drug delivery and drug release systems
- photodiagnosis/tumor imaging
- PDT-induced immunogenic cell death
- nanomaterials-based combination therapies